Arani Datta

Arani Datta

Auto-generated profile, based on publicly available information

Arani Datta

Department of Pediatrics, University of Texas Southwestern Medical Center

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
26 July 2018 in Blood
Verified
Journal Article
Closed access
PDF file
VPVijaya S. Pilli
Vijaya S. Pilli
ADArani Datta
Arani Datta
SASadaf Afreen
Sadaf Afreen
DCDonna Catalano
Donna Catalano
GSGyongyi Szabo
Gyongyi Szabo
Rinku MajumderRinku Majumder
Rinku Majumder
Publisher9s Note: There is a Blood Commentary on this article in this issue.

23 January 2015 in Molecular Cancer
Verified
Journal Article
Open access
PDF file
JFJohn Adams Fischer
John Adams Fischer
SRStefano Rossetti
Stefano Rossetti
ADArani Datta
Arani Datta
KEKevin H. Eng
Kevin H. Eng
ABAlessandro Beghini
Alessandro Beghini
NSNicoletta Sacchi
Nicoletta Sacchi
Core Binding Factor acute myeloid leukemia (CBF-AML) with t(8;21) RUNX1-MTG8 or inv(16) CBFB-MYH11 fusion proteins often show upregulation of wild type or mutated KIT receptor. However, also non-CBF-AML frequently displays upregulated KIT expression. In the first part of this study we show that KIT expression can be also upregulated by miR-17, a regulator of RUNX1, the gene encoding a CBF subunit. Interestingly, both CBF leukemia fusion proteins and miR-17, which targets RUNX1-3′UTR, negatively affect a common core RUNX1-miRNA mechanism that forces myeloid cells into an undifferentiated, KIT-induced, proliferating state. In the second part of this study we took advantage of the conservation of the core RUNX1-miRNA mechanism in mouse and human, to mechanistically demonstrate in a mouse myeloid cell model that increased KIT-induced proliferation is per se a mechanism sufficient to delay myeloid differentiation. Human (U937) or mouse (32D) myeloid clonal lines were used, respectively, to test: 1) the effect of RUNX1-MTG8 and CBFB-MYH11 fusion proteins, or upregulation of miR-17, on KIT-induced proliferation and myeloid differentiation, and 2) the effect of upregulation of KIT-induced proliferation per se on myeloid cell differentiation. In the first part of this study we found that stable miR-17 upregulation affects, like the CBF-AML fusion proteins (RUNX1-MTG8 or CBFB-MYH11), a core RUNX1-miRNA mechanism leading to KIT-induced proliferation of differentiation-arrested U937 myeloid cells. In the second part of the study we harnessed the conservation of this core mechanism in human and mouse to demonstrate that the extent of KIT upregulation in 32D mouse myeloid cells with wild type RUNX1 can per se delay G-CSF-induced differentiation. The integrated information gathered from the two myeloid cell models shows that RUNX1 regulates myeloid differentiation not only by direct transcriptional regulation of coding and non-coding myeloid differentiation functions (e.g. miR-223), but also by modulating KIT-induced proliferation via non-coding miRNAs (e.g. miR-221). The novelty of this study is dual. On the one hand, miRNAs (e.g. miR-17) can mimic the effects of CBF-AML fusion proteins by affecting a core RUNX1-miRNA mechanism of KIT-induced proliferation of undifferentiated myeloid cells. On the other hand, the extent of KIT-induced proliferation itself can modulate myeloid differentiation of cells with wild type RUNX1 function.

17 May 2024 in Microbes and Infection
Verified
Journal Article
Closed access
UBUmaru Barrie
Umaru Barrie
KFKatherine Floyd
Katherine Floyd
ADArani Datta
Arani Datta
DWDawn Marie Wetzel
Dawn Marie Wetzel

15 July 2023 in Journal of Cell Science
Verified
Journal Article
Open access
PDF file
IUImran Ullah
Imran Ullah
UBUmaru Barrie
Umaru Barrie
RKRebecca M. Kernen
Rebecca M. Kernen
EMEmily T. Mamula
Emily T. Mamula
FKFrancis Khuong
Francis Khuong
DWDawn Marie Wetzel
Dawn Marie Wetzel
Leishmania spp. are obligate intracellular parasites that must be internalized by phagocytic cells to evade immune responses and cause disease. The uptake of both Leishmania promastigotes (insect-stage parasites) and amastigotes (proliferative-stage parasites in humans and mice) by phagocytes is thought to be mainly host cell driven, not parasite driven. Our previous work indicates that host Src- and Abl-family kinases facilitate Leishmania entry into macrophages and pathogenesis in murine cutaneous leishmaniasis. Here, we demonstrate that host spleen tyrosine kinase (SYK) is required for efficient uptake of Leishmania promastigotes and amastigotes. A Src-family kinase–Abl-family kinase–SYK signaling cascade induces Leishmania amastigote internalization. Finally, lesion size and parasite burden during Leishmania infection is significantly decreased in mice lacking SYK in monocytes or by treatment with the SYK inhibitor entospletinib. In summary, SYK is required for maximal Leishmania uptake by macrophages and disease in mice. Our results suggest potential for treating leishmaniasis using host cell-directed agents.

15 July 2020 in Oncology Reports
Verified
Journal Article
Open access
VPVijaya Pilli
Vijaya Pilli
ADArani Datta
Arani Datta
ADAdrianne Dorsey
Adrianne Dorsey
BLBo Liu
Bo Liu
Rinku MajumderRinku Majumder
Rinku Majumder
Thrombotic complications and hypercoagulopathies are commonly associated with the progression of pancreatic ductal adenocarcinoma (PDAC). Although the mechanistic link between the two phenomena is uncertain, there is evidently an increase in procoagulant proteins and a decrease in anticoagulants in PDAC patients. For example, the anticoagulant protein S (PS) is decreased during the progression of PDAC, a condition that possibly contributes to the hypercoagulopathies. PS is also an important signaling molecule that binds a family of tyrosine kinase receptors known as TAM (Tyro3, Axl and Mer) receptors; TAM receptors are often upregulated in different cancers. Growth Arrest Specific 6 or GAS6 protein, a homolog of PS, is also a TAM receptor family ligand. The downstream signaling pathways triggered by this ligand‑receptor interaction perform diverse functions, such as cell survival, proliferation, efferocytosis, and apoptosis. Targeting the TAM receptors to treat cancer has had limited success; side effects are a significant obstacle due to the widespread numerous functions of TAM receptors. In the present study, it was revealed that PS‑TAM interaction was pro‑apoptotic, whereas GAS6‑mediated TAM signaling promoted proliferation and survival in select PDAC cell lines. Furthermore, by regulating the balance between these two signaling pathways (by overexpressing PS or knocking down GAS6), the proliferative potential of the cells was decreased. Both long‑term and short‑term effects of natural PS overexpression were comparable to the treatment of the cells with the drug UNC2025, which inhibits the Mer‑receptor. The present study lays the foundation for investigation of PS as a therapeutic agent to control cancer progression and to concurrently arrest thrombotic events.

1 October 2018 in Thrombosis Research
Verified
Journal Article
Closed access
WPWilliam E. Plautz
William E. Plautz
RCRima Chattopadhyay
Rima Chattopadhyay
EGEster I. Goldfeld
Ester I. Goldfeld
BSBenjamin J. Samelson-Jones
Benjamin J. Samelson-Jones
VPVijaya S. Pilli
Vijaya S. Pilli
Rinku MajumderRinku Majumder
Rinku Majumder